查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1703460

克拉黴素市場－全球產業規模、佔有率、趨勢、機會和預測，按銷售管道、最終用途、地區和競爭細分，2020-2030 年

Clarithromycin Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Sales Channel, By End Use, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球克拉黴素市值為 3.1908 億美元，預計到 2030 年將達到 4.149 億美元，預測期內年複合成長率(CAGR) 為 3.90%。市場成長主要源於針對多種細菌感染的有效抗生素治療需求的不斷成長。

市場概覽
預測期 2026-2030
2024年市場規模 3.1908億美元
2030年市場規模 4.149億美元
2025-2030 年複合年成長率 3.90%
成長最快的領域 直接的
最大的市場 亞太

克拉黴素是一種大環內酯類抗生素，廣泛用於治療呼吸道感染、皮膚感染和幽門螺旋桿菌引起的胃潰瘍。其廣譜抗菌功效和良好的安全性使其成為門診和住院環境中的首選治療選擇。

支持市場擴張的一個重要因素是肺炎、支氣管炎和鼻竇炎等呼吸系統疾病的發生率不斷上升，尤其是在受空氣污染嚴重和季節性氣候波動影響的地區。克拉黴素能夠針對多種革蘭氏陽性菌和革蘭氏陰性菌，這增強了其在這些疾病的治療方案中的作用。

此外，幽門螺旋桿菌感染負擔的增加（尤其是在發展中經濟體）繼續推動對克拉黴素聯合療法的需求。

關鍵市場促進因素

全球醫療保健產業的擴張

主要市場挑戰

更耐受的替代品的出現

主要市場趨勢

呼吸道感染盛行率不斷上升

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：COVID-19 對全球克拉黴素市場的影響

第5章：全球克拉黴素市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 按銷售管道（直接、間接）
    • 依最終用途（肺炎、支氣管炎、耳部感染、皮膚感染、咽喉感染、其他）
    • 按地區
    • 按公司分類（2024）
  • 市場地圖

第6章：北美克拉黴素市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第7章：歐洲克拉黴素市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太克拉黴素市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲

第9章：南美克拉黴素市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第10章：中東和非洲克拉黴素市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 驅動程式
  • 挑戰

第 12 章：市場趨勢與發展

  • 合併與收購（如有）
  • 產品發布（如有）
  • 最新動態

第 13 章：全球克拉黴素市場：SWOT 分析

第 14 章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品的威脅

第 15 章：競爭格局

  • Ercros SA
  • Guobang Pharmaceutical Group Co., Ltd
  • Synthimed Labs Private Limited
  • Cipla Ltd
  • Zhejiang Better Pharmaceuticals Co., Ltd.
  • Yichang Dongyang Sunshine Pharmaceutical Co., Ltd
  • Zhejiang Beide Pharmaceutical Co.,Ltd.
  • Huangshi Shi Xing Pharmaceutical Co., Ltd
  • Atom Pharma
  • Alembic Pharmaceuticals Limited

第 16 章：策略建議

第17章調查會社について,免責事項

簡介目錄
Product Code: 28250

The global clarithromycin market was valued at USD 319.08 million in 2024 and is projected to reach USD 414.90 million by 2030, expanding at a compound annual growth rate (CAGR) of 3.90% during the forecast period. Market growth is primarily driven by rising demand for effective antibiotic treatments targeting a wide spectrum of bacterial infections.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 319.08 Million
Market Size 2030USD 414.90 Million
CAGR 2025-20303.90%
Fastest Growing SegmentDirect
Largest MarketAsia-Pacific

Clarithromycin, a macrolide antibiotic, is extensively utilized in the treatment of respiratory tract infections, skin infections, and Helicobacter pylori-induced gastric ulcers. Its broad-spectrum antimicrobial efficacy and favorable safety profile have established it as a preferred therapeutic option across both outpatient and inpatient settings.

A significant factor supporting market expansion is the increasing incidence of respiratory diseases such as pneumonia, bronchitis, and sinusitis, particularly in regions affected by high air pollution levels and seasonal climatic fluctuations. Clarithromycin's ability to target a broad array of Gram-positive and Gram-negative bacteria reinforces its role in treatment protocols for these conditions.

Additionally, the rising burden of Helicobacter pylori infections-especially in developing economies-continues to drive demand for clarithromycin-based combination therapies.

Key Market Drivers

Expansion of the Global Healthcare Industry

The sustained growth of the global healthcare sector is a fundamental driver of the clarithromycin market. Healthcare constitutes one of the largest and fastest-growing industries worldwide. In several developed nations, healthcare spending exceeds 10% of GDP, underlining its economic significance. For example, U.S. healthcare expenditure rose by 2.7% in 2021 to approximately USD 4.3 trillion, averaging USD 12,914 per capita.

As healthcare systems worldwide scale to meet rising patient volumes and adopt evolving treatment protocols, the demand for reliable, broad-spectrum antibiotics such as clarithromycin continues to grow. The antibiotic's widespread use in treating respiratory infections, H. pylori-related conditions, and skin infections positions it to benefit from this sector-wide expansion.

Key Market Challenges

Emergence of Better-Tolerated Alternatives

Despite its established clinical utility, the clarithromycin market is facing growing competitive pressure due to the availability of newer antibiotics with improved tolerability profiles. Although clarithromycin remains a mainstay in treating various infections, the introduction of alternative macrolides and other antibiotic classes is gradually impacting its market share.

Adverse gastrointestinal effects-including nausea, abdominal discomfort, and diarrhea-pose notable concerns with clarithromycin usage. Furthermore, potential drug interactions, particularly among patients on cardiovascular medications, have raised caution among prescribers. As a result, alternatives like azithromycin are increasingly preferred due to their more convenient dosing schedules, reduced risk of drug-drug interactions, and enhanced patient compliance.

Key Market Trends

Increasing Prevalence of Respiratory Infections

The growing prevalence of respiratory infections is a prominent trend influencing demand for clarithromycin. Recognized for its efficacy in managing both upper and lower respiratory tract infections-such as sinusitis, bronchitis, and community-acquired pneumonia-clarithromycin remains a critical therapeutic agent.

Rising pollution levels, urbanization, and climate change have contributed to an increase in respiratory illnesses globally. For instance, in China, influenza is currently the most frequently reported respiratory pathogen in individuals with acute respiratory infections. According to the World Health Organization (WHO), there is no indication of unusual outbreak patterns, and healthcare systems remain within operational capacity. WHO continues to monitor respiratory disease trends globally through established surveillance systems.

Pollutants and fine particulate matter are exacerbating respiratory conditions, increasing population vulnerability to infections. This has led to higher antibiotic prescription rates, with clarithromycin favored due to its broad antimicrobial range and favorable safety profile.

Key Market Players

  • Ercros S.A
  • Guobang Pharmaceutical Group Co., Ltd
  • Synthimed Labs Private Limited
  • Cipla Ltd
  • Zhejiang Better Pharmaceuticals Co., Ltd.
  • Yichang Dongyang Sunshine Pharmaceutical Co., Ltd
  • Zhejiang Beide Pharmaceutical Co.,Ltd.
  • Huangshi Shi Xing Pharmaceutical Co., Ltd
  • Atom Pharma
  • Alembic Pharmaceuticals Limited

Report Scope

In this report, the Global Clarithromycin Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Clarithromycin Market, By Sales Channel:

  • Direct
  • Indirect

Clarithromycin Market, By End Use:

  • Pneumonia
  • Bronchitis
  • Ear Infection
  • Skin Infection
  • Throat Infection
  • Others

Clarithromycin Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Clarithromycin Market.

Available Customizations:

Global Clarithromycin Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Clarithromycin Market

5. Global Clarithromycin Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Sales Channel (Direct, Indirect)
    • 5.2.2. By End Use (Pneumonia, Bronchitis, Ear Infection, Skin Infection, Throat Infection, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Clarithromycin Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Sales Channel
    • 6.2.2. By End Use
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Clarithromycin Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Sales Channel
        • 6.3.1.2.2. By End Use
    • 6.3.2. Mexico Clarithromycin Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Sales Channel
        • 6.3.2.2.2. By End Use
    • 6.3.3. Canada Clarithromycin Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Sales Channel
        • 6.3.3.2.2. By End Use

7. Europe Clarithromycin Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Sales Channel
    • 7.2.2. By End Use
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Clarithromycin Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Sales Channel
        • 7.3.1.2.2. By End Use
    • 7.3.2. Germany Clarithromycin Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Sales Channel
        • 7.3.2.2.2. By End Use
    • 7.3.3. United Kingdom Clarithromycin Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Sales Channel
        • 7.3.3.2.2. By End Use
    • 7.3.4. Italy Clarithromycin Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Sales Channel
        • 7.3.4.2.2. By End Use
    • 7.3.5. Spain Clarithromycin Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Sales Channel
        • 7.3.5.2.2. By End Use

8. Asia Pacific Clarithromycin Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Sales Channel
    • 8.2.2. By End Use
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Clarithromycin Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Sales Channel
        • 8.3.1.2.2. By End Use
    • 8.3.2. India Clarithromycin Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Sales Channel
        • 8.3.2.2.2. By End Use
    • 8.3.3. South Korea Clarithromycin Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Sales Channel
        • 8.3.3.2.2. By End Use
    • 8.3.4. Japan Clarithromycin Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Sales Channel
        • 8.3.4.2.2. By End Use
    • 8.3.5. Australia Clarithromycin Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Sales Channel
        • 8.3.5.2.2. By End Use

9. South America Clarithromycin Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Sales Channel
    • 9.2.2. By End Use
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Clarithromycin Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Sales Channel
        • 9.3.1.2.2. By End Use
    • 9.3.2. Argentina Clarithromycin Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Sales Channel
        • 9.3.2.2.2. By End Use
    • 9.3.3. Colombia Clarithromycin Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Sales Channel
        • 9.3.3.2.2. By End Use

10. Middle East and Africa Clarithromycin Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Sales Channel
    • 10.2.2. By End Use
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Clarithromycin Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Sales Channel
        • 10.3.1.2.2. By End Use
    • 10.3.2. Saudi Arabia Clarithromycin Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Sales Channel
        • 10.3.2.2.2. By End Use
    • 10.3.3. UAE Clarithromycin Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Sales Channel
        • 10.3.3.2.2. By End Use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Clarithromycin Market: SWOT Analysis

14. Porters Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Ercros S.A
    • 15.1.1. Business Overview
    • 15.1.2. Company Snapshot
    • 15.1.3. Products & Services
    • 15.1.4. Financials (As Reported)
    • 15.1.5. Recent Developments
    • 15.1.6. Key Personnel Details
    • 15.1.7. SWOT Analysis
  • 15.2. Guobang Pharmaceutical Group Co., Ltd
  • 15.3. Synthimed Labs Private Limited
  • 15.4. Cipla Ltd
  • 15.5. Zhejiang Better Pharmaceuticals Co., Ltd.
  • 15.6. Yichang Dongyang Sunshine Pharmaceutical Co., Ltd
  • 15.7. Zhejiang Beide Pharmaceutical Co.,Ltd.
  • 15.8. Huangshi Shi Xing Pharmaceutical Co., Ltd
  • 15.9. Atom Pharma
  • 15.10. Alembic Pharmaceuticals Limited

16. Strategic Recommendations

17. About Us & Disclaimer